Answers are grounded in this paper and cite their sources.
Background: Adenocarcinoma of the esophagogastric junction (AEG) remains a highly lethal disease despite multimodal therapy. The interplay between fibroblast growth factor (FGF) signaling and immune-checkpoint regulation in AEG is poorly understood. This study investigated the associations between FGF8, FGF18, and FGFR4 expression and PD-1/PD-L1/PD-L2 expression. Methods: In a cohort of 117 resected AEG cases, immunohistochemical expression of FGF8, FGF18, PD-1, PD-L1, and PD-L2 was analyzed. Associations were assessed using chi-square tests and Pearson correlation analyses. Combined FGF8–FGF18 expression groups and survival outcomes were evaluated using Kaplan–Meier analysis. Results: The updated correlation analysis included 107 cases and identified a weak inverse association between FGF8 expression and PD-L1 expression in tumor cells (r = −0.175, p = 0.036). No statistically significant correlations were observed between FGF18 expression and the investigated immune-checkpoint markers. Clinically, FGF18 was associated with advanced pT stage (p < 0.001) and postoperative UICC classification (p = 0.005), while both FGF8 (p = 0.022) and FGF18 (p = 0.015) were associated with lymph node metastasis. In the combined FGF8–FGF18 analysis, PD-1-negative lymphocytes occurred exclusively in the low-FGF8/low-FGF18 group (p = 0.042). Kaplan–Meier analysis demonstrated significantly poorer survival in FGF8-high tumors (p < 0.001). Conclusions: FGF8 was associated with poorer overall survival and showed a weak inverse association with PD-L1 expression in tumor cells. FGF18 was not significantly correlated with the investigated immune-checkpoint markers. The association between combined FGF8–FGF18 expression patterns and PD-1 positivity in lymphocytes warrants further investigation.
No takes yet. Share an insight, caveat, or question.
Jomrich et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: